Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.

Through a structure-guided rational drug design approach, we have discovered a highly selective inhibitor compound 40 (JSH-150), which exhibited an IC50 of 1 nM against CDK9 kinase in the biochemical assay and achieved around 300-10000-fold selectivity over other CDK kinase family members. In addition, it also displayed high selectivity over other 468 kinases/mutants (KINOMEscan S score(1) = 0.01). Compound 40 displayed potent antiproliferative effects against melanoma, neuroblastoma, hepatoma, colon cancer, lung cancer as well as leukemia cell lines. It could dose-dependently inhibit the phosphorylation of RNA Pol II, suppress the expression of MCL-1 and c-Myc, arrest the cell cycle and induce the apoptosis in the leukemia cells. In the MV4-11 cell-inoculated xenograft mouse model, 10 mg/kg dosage of 40 could almost completely suppress the tumor progression. The high selectivity and good in vivo PK/PD profile suggested that 40 would be a good pharmacological tool to study CDK9-mediated physiology and pathology as well as a potential drug candidate for leukemia and other cancers.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.09.025PMID 30253346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

  2019cited by this paper
• Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.

  2017cited by this paper
• Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.

  2017cited by this paper
• Recent advances on CDK inhibitors: An insight by means of in silico methods.

  2017cited by this paper
• Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

  2016cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

  2015cited by this paper
• Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities

  2013cited by this paper
• A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine

  2013cited by this paper
• Principles and applications of halogen bonding in medicinal chemistry and chemical biology.

  2013cited by this paper
• Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs

  2013cited by this paper
• Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

  2012cited by this paper
• Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1

  2011cited by this paper
• Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.

  2010cited by this paper
• Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

  2010cited by this paper
• CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells.

  2010cited by this paper
• Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

  2010cited by this paper
• AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

  2009cited by this paper
• Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

  2009cited by this paper
• Cell cycle kinases as therapeutic targets for cancer

  2009cited by this paper
• SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

  2009cited by this paper
• RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDKDependent and Independent Survival Mechanisms

  2008cited by this paper
• Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.

  2008cited by this paper
• Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Elongation by RNA polymerase II: the short and long of it.

  2004cited by this paper
• N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.

  2004cited by this paper
• Transcriptional activity of P-TEFb kinase in vivo requires the C-terminal domain of RNA polymerase II.

  2000cited by this paper
• Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.

  2000cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

  1994cited by this paper
• D-type cyclin-dependent kinase activity in mammalian cells

  1994cited by this paper
• Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs.

  1989cited by this paper

• Discovery of a Novel Dihydroisoquinolinone Derivative as a Potent CDK9 Inhibitor Capable of Overcoming L156F Mutant for the Treatment of Hematologic Malignancies.

  2025cites this paper
• In silico-driven identification of potent CDK9 inhibitors through bioisosteric replacement and multi-stage virtual screening

  2025influential citation
• Design, synthesis, and activity evaluation of selective CDK9 inhibitors containing indazole fragments.

  2025cites this paper
• Convenient syntheses of 2-acylamino-4-halothiazoles and acylated derivatives using a versatile Boc-intermediate

  2024cites this paper
• CDK9 inhibitors for the treatment of solid tumors.

  2024cites this paper
• Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.

  2024cites this paper
• Bromo-substituted indirubins for inhibition of protein kinase-mediated signalling involved in inflammatory mediator release in human monocytes.

  2024cites this paper
• Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.

  2024cites this paper
• A high-throughput platform for single-molecule tracking identifies drug interaction and cellular mechanisms

  2024cites this paper
• CDK2-based CDK7 mimic as a tool for structural analysis: Biochemical validation and crystal structure with SY5609.

  2024cites this paper
• Heterocyclic Compounds as CDK9 Inhibitors: Structural Diversity, Mechanism of Action, and Therapeutic Potential in Cancer and Beyond

  2024cites this paper
• Design and optimization of selective and potent CDK9 inhibitors with flavonoid scaffold for the treatment of acute myeloid leukemia.

  2023cites this paper
• CDK7 and CDK9 inhibition interferes with transcription, translation and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity.

  2023cites this paper
• Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

  2023cites this paper
• Thiazole, isatin and phthalimide derivatives tested in vivo against cancer models: a literature review of the last six years.

  2023cites this paper
• Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.

  2023cites this paper
• The Application of pyrrolo[2, 3-d]pyrimidine scaffold in medicinal chemistry from 2017 to 2021.

  2023cites this paper
• Distinct states of nucleolar stress induced by anticancer drugs

  2023cites this paper
• Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer.

  2022cites this paper
• CDK9 inhibitors in cancer research.

  2022cites this paper
• Molecular insights on selective and specific inhibitors of Cyclin Dependent Kinase 9 enzyme (CDK9) for the purpose of cancer therapy.

  2022cites this paper
• Chemical inhibitors of transcription-associated kinases.

  2022cites this paper
• Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.

  2022cites this paper
• Discovery of Pongol, the Furanoflavonoid, as an Inhibitor of CDK7/Cyclin H/MAT1 and Its Preliminary Structure–Activity Relationship

  2022cites this paper
• Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.

  2021cites this paper
• Current developments in the Pyran-Based Analogues as Anticancer Agents.

  2021cites this paper
• Discovery of N-(4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)quinazolin-7-amine as a Novel, Potent, and Oral Cyclin-Dependent Kinase Inhibitor against Haematological Malignancies.

  2021cites this paper
• A Deep Learning Based Scaffold Hopping Strategy for the Design of Kinase Inhibitors

  2021cites this paper
• Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches

  2021cites this paper
• Regioselective Pd-catalyzed α-alkylation of furans using alkyl iodides

  2021cites this paper
• Targeting CDK9 for Anti-Cancer Therapeutics

  2021cites this paper
• Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy

  2021cites this paper
• Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

  2020cites this paper
• Design, Synthesis, and Molecular Docking of Paracyclophanyl-Thiazole Hybrids as Novel CDK1 Inhibitors and Apoptosis Inducing Anti-Melanoma Agents

  2020cites this paper
• Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway

  2020cites this paper
• A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.

  2020cites this paper
• A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II-Biological functions and inhibitors.

  2020cites this paper
• Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation.

  2020cites this paper
• Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

  2019cites this paper
• Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.

  2019cites this paper
• Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.

  2019cites this paper
• Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles.

  2018cites this paper